Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The trial is a single-centre, randomized, double-blind, parallel trial in Group 1 and
cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic
Type 1 diabetic patients to evaluate the pharmacokinetics and pharmacodynamics of ZP4207 as
compared to marketed glucagon.